Latest / Stock Movers / SAP Beats, Sanofi Dips, Arcadis Gains
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Let's take a look now at some stocks on the
- 0:18Speaker 3: move today in Europe. I'm Rich Levens with Stephen Carroll,
- 0:20Speaker 3: and we're joined by Bloomberg's Breaking news editor Luise Moon. Luis,
- 0:24Speaker 3: thanks for joining us. SAP had some pretty good earnings overnight.
- 0:28Speaker 3: Tell us a bit more about what investors are reacting
- 0:30Speaker 3: to today.
- 0:30Speaker 1: Indeed, this is their second quarter earnings and positive reactions
- 0:34Speaker 1: to this, so the focus being on their better than
- 0:36Speaker 1: expected sales for their cloud products. So SAP has been
- 0:39Speaker 1: pushing customers essentially to upgrade systems at a faster pace,
- 0:43Speaker 1: adopt their AI products, and this seems to be paying off.
- 0:46Speaker 1: So shares roads today about six percent roughly in Frankfurt,
- 0:50Speaker 1: which is a good boost given that so far they
- 0:52Speaker 1: see if they've fallen about thirty five percent, that was
- 0:55Speaker 1: all on those concerns over AI, so that their advances
- 0:58Speaker 1: and AI wouldn't being picked up fast enough and they
- 1:01Speaker 1: would fall behind. So those better cloud sales seem like
- 1:04Speaker 1: they're easing investor concern, so analysts are saying they do
- 1:07Speaker 1: still have some catching up to do against competitors to
- 1:10Speaker 1: make their AI story a bit more compelling.
- 1:12Speaker 3: But this strong growth in cloud products.
- 1:15Speaker 1: Is a good sign, so boosting shares in trading in
- 1:18Speaker 1: Germany this morning.
- 1:19Speaker 3: Okay, so that's an sap. Let's go to Santa Finex
- 1:22Speaker 3: acting the development of a new exema drug.
- 1:24Speaker 1: Indeed, yeah, so they're ending the clinical development. This is
- 1:28Speaker 1: for a type of dermatitis, essentially saying that the eficacy
- 1:31Speaker 1: and the safety evidence in what was a late stage
- 1:34Speaker 1: trial doesn't support further developments. They're not going to submit
- 1:37Speaker 1: it for regulatory review. And this is a relatively big deal.
- 1:42Speaker 1: Bloomberg Intelligence had estimated that the sales potential of this
- 1:45Speaker 1: drug could be up to about five billion US dollars,
- 1:48Speaker 1: so shares falling on the back of that for about
- 1:50Speaker 1: one point two percent this year, and then in the
- 1:53Speaker 1: wider context of the whole company, it's quite a blow
- 1:56Speaker 1: to the relatively new CEO. So she's been trying to
- 2:00Speaker 1: essentially get new drivers of revenue like this drug before
- 2:03Speaker 1: their top selling drug patent expires, which is in twenty
- 2:06Speaker 1: thirty one. So she's been trying to kind of beef
- 2:08Speaker 1: up their pipeline in expectation of that happening. So this
- 2:12Speaker 1: is putting more or puts more pressure on her unless
- 2:16Speaker 1: is saying, you know, it leaves the company without many
- 2:19Speaker 1: late stage assets, intensified that need for that pipeline to
- 2:22Speaker 1: be built out more and also therefore potentially raises the
- 2:26Speaker 1: pressure on her to pursue a more of an M
- 2:28Speaker 1: and a approach, so more deals. So what we can
- 2:30Speaker 1: be an id to see if that happens. But yeah,
- 2:32Speaker 1: shares down on that news this morning, and.
- 2:34Speaker 3: They're also seeing Gainesparcadis what's been going on there.
- 2:37Speaker 1: So they've been approached for a second time to be bought.
- 2:41Speaker 1: Circadis is a consulting and engineering firm based in Amsterdam.
- 2:45Speaker 1: They've got a second unsisted bid from a Canadian pier
- 2:48Speaker 1: so they're called WSP Global. That would value Ourcadis at
- 2:52Speaker 1: four point seven billion euros. So it's a big potential
- 2:55Speaker 1: amine deal if that weren't happen. They've previously rejected a
- 2:58Speaker 1: lower offer. They said that it doesn't reflect the value
- 3:00Speaker 1: their strategy, their vision for the future. So shares rising
- 3:04Speaker 1: this morning twelve percent, so that's the most since late
- 3:07Speaker 1: April for Arcadis. They're saying that they're still highly confident
- 3:11Speaker 1: in their strategy, their outlook, So we'll have to see
- 3:14Speaker 1: if and when this potentially comes through, if there's higher bids,
- 3:18Speaker 1: changes of bids or yeah, or the keep and eye
- 3:22Speaker 1: see if there's any emine action with that.
- 3:25Speaker 2: The Stock Movers Report from Bloomberg Radio. Check back with
- 3:29Speaker 2: us throughout the day for the latest roundup of companies
- 3:31Speaker 2: making news on Wall Street and for the latest market
- 3:35Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 3:39Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 3:43Speaker 2: the Bloomberg Business app.